ITS
InsiderTrading
TradesInsidersCompaniesCluster BuysRankingsAbout
ITS
InsiderTrading Screener

Track SEC Form 4 insider trades. See what corporate insiders are buying and selling.

Browse

  • Trades
  • Insiders
  • Companies
  • Cluster Buys
  • Rankings

Top Insiders

  • Mark Zuckerberg
  • Elon Musk
  • Jamie Dimon
  • Satya Nadella
  • Lisa Su
  • Jensen Huang

Screeners

  • CEO & CFO Purchases
  • Director Purchases
  • Top Buys This Week
  • Top Sales This Week
  • 10b5-1 Trades
  • Buy/Sell Ratios
  • Politician Overlap
  • Sectors

Learn

  • Learn
  • What is a Form 4?
  • About & Methodology
  • What are Cluster Buys?
  • Top Insider Rankings
  • Privacy Policy
  • Terms of Use

Data

  • SEC EDGAR Form 4 ↗
  • CongressStock.com ↗
  • Track13F.com ↗
  • About the data
© 2026 InsiderTradingScreener.com. Data from SEC EDGAR Form 4 filings.For informational purposes only. Not financial advice.
Home / Trades / #488318

ROBINS HARLAN S sold ADPT

July 21, 2026 · Form 4 insider transaction

ROBINS HARLAN S sold 213,702 shares of Adaptive Biotechnologies Corporation at $22.12 per share, a transaction worth $4.73M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
213,702
Price
$22.12
Total value
$4.73M
InsiderROBINS HARLAN S
Role—
CompanyAdaptive Biotechnologies Corporation (ADPT)
SecurityCommon Stock
Transaction codeS — Open-market sale
Transaction dateJuly 21, 2026
Filing dateJuly 23, 2026
Shares owned after812,058
OwnershipDirect
10b5-1 planYes
AmendedNo

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.; The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

View the original Form 4 on SEC EDGAR